FDA Commissioner Robert Califf did not want politics interfering with the controversial approval of Sarepta Therapeutics Inc.'s Duchenne muscular dystrophy drug Exondys 51 and decided to stay out of it.
"While it is essential for FDA to be collaborative with the community of patients, advocates, academia and industry during development,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?